Technical Data
T8065-11
Topoisomerase II (DNA) alpha
Description:
The expression of topoisomerase II alpha is strongly restricted to proliferating cells. The topoisomerase II alpha antigen is preferentially expressed during G1, S, G2 and M phase of the cell cycle, while resting, non-cycling cells (G0 phase) lack topoisomerase II alpha. In addition, constantly proliferating cells (e.g. cell lines) react positively to topoisomerase II alpha during the entire cell-cycle. This specificity for proliferating cells might make it a useful tool for determination of the proliferative fraction in solid tumors such as mammary carcinomas and gangliomas.

Applications:
Suitable for use in Immunohistochemistry, Western Blot, Immunoprecipitation, Immunocytochemistry and Flow Cytometry. Other applications not tested.

Recommended Dilutions:
Western Blot: 1-10ug/ml
Immunohistochemistry: 5-10ug/ml. Strong nuclear staining only in proliferating cells. The epitope recognized by the antibody is also detectable in paraffin-embedded tissue sections.
Immunocytochemistry: 5-10ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

TypeIsotypeCloneGrade
MabIgG2a2Q382Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Nuclear protein preparation from the human cell line U937.50
Purity:
Purified
Form
Supplied as a liquid in PBS, pH 7.6, 0.1% sodium azide.
Specificity:
Recognizes a major protein of 170kD which was identified as the human alpha isoform of topoisomerase II. Recognizes a C- terminal alpha-isoenzyme specific epitope missing in topoisomerase II beta.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1 Boege, F. et al. (1995) Am. J. Pathol., June (accepted). 2 Kreipe, H. et al. (1993) Am. J. Pathol. 142, 651. 3 Kreipe, H. et al. (1993) Am. J. Pathol. 142, 3. 4 Tsutsui, K. et al. (1993) J. Biol. Chem. 268, 19076 5 Sampson, S.A. et al. (1992) J. of Pathology 168, 179. 6 Camplejohn, R.S. et al. (1993) Br. J. Cancer 67, 657. 7 Kreipe, H. et al (1993) Cancer Research 53, 1956. 8 Rasbridge et al (1994) Br. J. Cancer 70, 335 9 Wolf, H. K. et al (1994) ACTA Neuropathologica 88, 166.